FindMyKOL
Clinical trialNCT05145816RecruitingPhase 1/PHASE2Interventional

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

SponsorUniversity of Texas Southwestern Medical CenterEnrollment37AL AmyloidosisAmyloidosis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this study is to test the safety of drug, Belantamab Mafodotin, and see what effects (good and bad) it has on people who take it and have amyloidosis, and to determine the most effective dose of the drug. The study will have 2 phases (parts). The first phase of the study will test different doses of Belantamab Mafodotin. The second phase will test Belantamab Mafodotin at the dose level found to be safe and effective in phase 1
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee, United States

    Eden Biltibo, MD
    Recruiting
  • Ut Southwestern Medical Center

    Dallas, Texas, United States

    Larry Anderson, MD
    Recruiting
  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah, United States

    Amandeep Godara, MBBS
    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Belantamab mafodotin 1.0 mg/kgBelantamab mafodotin 1.4 mg/kgBelantamab mafodotin 1.9 mg/kgBelantamab mafodotin 2.5 mg/kgBelantamab mafodotin every 8 weeks or 12 weeks as determined by Part 1 recommended dosages
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 Feb 2024
Primary completion
1 Mar 2027
Completion
1 Sept 2027
Last update posted
19 Aug 2026
Registered enrollment
37
Registry id
NCT05145816
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.